Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bridgepoint Development Capital to Acquire Quotient Clinical

Published: Wednesday, December 11, 2013
Last Updated: Wednesday, December 11, 2013
Bookmark and Share
Quotient Clinical has been acquired from the Quotient Bioresearch Group by Bridgepoint Development Capital for an undisclosed sum.

Employing over 200 people, Quotient Clinical has developed a platform which offers an integrated approach to formulation development, “real-time” drug product manufacturing and clinical testing.  Using this platform has been proven to significantly reduce the time and cost of the early stage drug development process.

The company serves a global customer base comprising a range of top tier pharmaceutical companies through to small-medium sized biotech organisations. More than three quarters of its revenues are derived from customers based in the USA or mainland Europe.  It has two operational facilities in the UK. The principal site in Nottingham, has a certified 85 bed clinical pharmacology unit with an integrated drug manufacturing facility employing formulation chemists, and clinical staff including nurses and doctors. The second facility in Edinburgh houses the companies’ Biometrics function responsible for the analysis and reporting of clinical trial data.

The outsourced drug development market is currently valued at $30 billion and is forecast to grow at up to 6% p.a. and is characterised by a focus on speed to market to maximise value from a drug’s period under patent.  The addressable market for Quotient’s services derives from its so called ‘Translational Pharmaceutics’ platform is conservatively estimated to be worth over $400 million pa.

Quotient Clinical Chief Executive Officer Mark Egerton said: “We are very excited at the pace with which our platform is being adopted in the marketplace. Working with Bridgepoint Development Capital will now provide the support to catalyse the next phase of our growth and evolution.  Their experience in helping portfolio companies to scale will be invaluable as we endeavour to grow our business and maintain the high levels of customer satisfaction that we currently enjoy”.

Alan Payne, partner at Bridgepoint Development Capital, said: “Quotient Clinical serves a substantial and growing market and there is significant opportunity to increase market penetration thanks to its combination of unique service offering, strong regulatory governance and a talented management team.”

Quotient Clinical is currently part of Quotient Group which is disposing of the business and represents a primary management buyout. The transaction is subject to standard regulatory clearances.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Automated Patch Clamping Trends
Learn more about current practices, preferences and metrics in ion channel drug screening using APC technology.
Mechanisms of Calcium Blockers
Researchers describe how the fundamental mode of action of two distinct chemical classes of calcium channel blockers differs.
Breakthrough in GPCR Understanding
Integral Molecular announces breakthrough in understanding the functionality of GPCRs, the largest class of drug targets in human disease.
Enzyme that Triggers Cell Demise in ALS Identified
Scientists from Harvard have identified a key instigator of nerve cell damage in people with amyotrophic lateral sclerosis (ALS).
Fly Study into Therapies for HVP-Induced Cancer
Fruit flies may help scientists understand the mechanism by which HPV can cause cancer as well as identify potential drug treatments.
World's Most In-Depth Study to Detect Alzheimer's Disease
A multisite team will see the most thorough and vigorous testing for Alzheimer's ever performed on volunteers.
'Missing Evolutionary Link' of Natural Drug Source Found
Scripps Florida study finds 'missing evolutionary link' of a widely used natural drug source
Grad Student's Finding Enables Rapid Compound Screening
Grad student makes technical leap that could enable rapid screening of anti-cancer compounds.
Uncovering Constructor Proteins
Scientists have discovered a new bacterial cell wall builder that could be a target for antibiotic development.
Cholesterol Linked to Aggressive Cancers
Research suggests fats, such as cholesterol, can increase aggressive cancer progression.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!